Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CardieX ( (AU:CDX) ) has issued an update.
Cardiex Limited has announced an unmarketable parcel share buy-back, allowing shareholders with holdings valued at less than A$500 to sell their shares back to the company at A$0.03 per share. This initiative, in accordance with the company’s constitution and ASX Listing Rules, aims to streamline operations by canceling these shares once transferred. Eligible shareholders must submit a retention form by October 13, 2025, if they wish to retain their shares. The buy-back is set to conclude with proceeds remitted to shareholders by October 23, 2025, subject to potential changes by the company.
More about CardieX
Cardiex is a company focused on advancing medical technology for vascular health, offering products such as medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Their offerings are based on the SphygmoCor® vascular biomarker technology, and they are listed on the Australian Stock Exchange (ASX: CDX).
Average Trading Volume: 447,789
Technical Sentiment Signal: Sell
Current Market Cap: A$16.5M
For an in-depth examination of CDX stock, go to TipRanks’ Overview page.